

Short communication

Recombinant production of active microbial transglutaminase in *E. coli* by using self-cleavable zymogen with mutated propeptide.

Ryo Sato,^a Kosuke Minamihata,^a * Ryutarō Ariyoshi,^a Hiromasa Taniguchi,^a and Noriho Kamiya^{a, b}

^a*Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motoooka, Fukuoka 819-0395, Japan.*

^b*Division of Biotechnology, Center for Future Chemistry, Kyushu University, 744 Motoooka, Fukuoka 819-0395, Japan.*

*Corresponding author. E-mail address: kosukeminami@mail.cstm.kyushu-u.ac.jp

Keywords: microbial transglutaminase, *Streptomyces mobaraensis*, zymogen, self-cleavable, chimera protein.

Abstract

Microbial transglutaminase from *Streptomyces mobaraensis* (MTG) has been widely used in food industry and also in research and medical applications, since it can site-specifically modify proteins by the cross-linking reaction of glutamine residue and the primary amino group. The recombinant expression system of MTG in *E. coli* provides better accessibility for the researchers and thus can promote further utilization of MTG. Herein, we report production of active and soluble MTG in *E. coli* by using a chimeric protein of tobacco etch virus (TEV) protease and MTG zymogen. A chimera of TEV protease and MTG zymogen with native propeptide resulted in active MTG contaminated with cleaved propeptide due to the strong interaction between the propeptide and catalytic domain of MTG. Introduction of mutations of K10R and Y12A to the propeptide facilitated dissociation of the cleaved propeptide from the catalytic domain of MTG and active MTG without any contamination of the propeptide was obtained. The specific activity of the active MTG was 22.7 ± 2.6 U/mg. The successful expression and purification of active MTG by using the chimera protein of TEV protease and MTG zymogen with mutations in the propeptide can advance the use of MTG and the researches using MTG mediated cross-linking reactions.

Transglutaminase (TGases, protein-glutamine γ -glutamyltransferase, E.C. 2.3.2.13) catalyzes acyl transfer reaction between γ -carboxamide groups of glutamine residues and primary amine including ϵ -amino groups of lysine residues. Among many transglutaminases from different sources (Griffin et al., 2002), a microbial transglutaminase from *Streptomyces mobaraensis* (MTG) is the one studied the most and is commercially available today ((Strop, 2014). Although the main application of MTG is in food industry (Kieliszek and Misiewicz, 2014; Motoki and Seguro, 1998), MTG has been used as a ligation tool for proteins in research (Milczek, 2018) and pharmaceutical fields (Schneider et al., 2020). MTG-mediated site-specific conjugations of proteins with small functional molecules (Kamiya et al., 2009), protein (Hirakawa et al., 2007), DNA (Kitaoka et al., 2011; Takahara et al., 2017), RNA (Kitaoka et al., 2012), synthetic polymers (Wakabayashi et al., 2017), and lipids (Takahara et al., 2019) have been reported. Moreover, MTG is utilized to conjugate anticancer agents to antibody to make antibody-drug conjugates (ADCs) for medical use (Dennler et al., 2014; Walker et al., 2019). For those researches and uses, the precise control of reaction condition is necessary to achieve site-specific modifications of proteins and correct assessment of the obtained results and thus a highly purified MTG is needed. The commercial MTG products for food industry are cheap, however, they contain a lot of additives as well as other proteinous substances, and thus further purification is required before use. A commercial MTG with high purity and activity is available from Zedira (Germany), yet its price is rather expensive for routine use. Therefore, it is meaningful to develop an *E. coli* expression system of MTG for laboratory use with high purity and activity.

In nature, MTG is produced as a zymogen, carrying a propeptide at the N-terminus of matured MTG domain and proteolysis of the propeptide is required for activation of MTG (Marx et al., 2007). The propeptide has a function of intramolecular chaperone and thus the expression of MTG without the propeptide in *E. coli* results in the formation of inclusion body (Kawai et al., 1997).

The active MTG can be made by refolding from the inclusion body (Yokoyama et al., 2000) or by removing the propeptide from MTG zymogen by protease treatment (Marx et al., 2008). However, these strategies are not straightforward, because additional refolding process or protease treatment process as well as another purification steps after proteolysis are needed.

One step expression of the active MTG in *E. coli* has been demonstrated by polycistronic expression of the propeptide and the matured MTG domain in *E. coli* (Liu et al., 2011; Javitt et al., 2017). Both were secreted into the periplasmic space and the propeptide facilitated the folding of matured MTG domain and active MTG was obtained in soluble form without any additional downstream processes. Another approach was to co-express MTG zymogens with a protease (Rickert et al., 2016). MTG zymogens with 3C protease recognition sequence between the propeptide and matured MTG domain were successfully processed by the co-expressed 3C protease in *E. coli* and active MTG was obtained. For both strategies, the expression level of two genes would have impact on the overall yield of active MTG. The simplest but the most precise way to control the expression ratio of two proteins is to genetically fuse and express them as a single polypeptide.

Herein we report another strategy to make active MTG in soluble form by constructing a chimera protein of a protease and MTG zymogen. Tobacco etch virus (TEV) protease was selected to cleave off the propeptide from MTG zymogen. Two constructs of chimera proteins of TEV protease and MTG zymogen were constructed by using pMAL-c5E vector (**Fig. 1A**). Both constructs contain maltose-binding protein (MBP) at the N-termini to promote the correct folding of the chimera proteins and to increase the solubility of them. The N-terminal amino group of Gly can be a substrate of MTG reaction (Tanaka et al., 2005). Therefore, to prevent self-cross-linking of MTG after propeptide cleavage by TEV protease, a TEV protease recognition sequence of GSENL~~Y~~FQ↓SGG was inserted between the propeptide and matured MTG domain in MBP-TEV-Pro-MTG (**Fig. 1B**). It's been reported that the modulation of interaction between

propeptide and the catalytic domain of MTG was key to increase the productivity of active MTG (Rickert et al., 2016). Moreover, in this study, we put another mutation of K10R in the propeptide to eliminate possibility of cross-linking of MTG zymogen via K10. MBP-TEV-Pro(K10R/Y12A)-MTG has mutations of K10R and Y12A in the propeptide and a longer TEV protease recognition sequence (GGGSENLVYFQSGGGGS) than MBP-TEV-Pro-MTG with deleting 8 amino acid residues (AGPSFRAP) at the C-terminal of propeptide (**Fig. 1C**) The whole amino acid sequences of constructed MTG variants were provided in Supplementary Information as **Table S1**. We anticipated the mutations in the propeptide attenuate the interaction towards the catalytic domain of MTG and facilitate dissociation of the propeptide from active-MTG after self-cleavage (**Fig. 1D**).




Fig. 1. Constructs of MTG variants evaluated in this study. A: Schematic illustrations of DNA constructs of pMAL-TEV-Pro-MTG and pMAL-TEV-Pro(K10R/Y12A)-MTG. B and C: Schematic illustrations of MBP-TEV-Pro-MTG and MBP-TEV-Pro(K10R/Y12A)-MTG, respectively. D: Self-cleavage reaction of MBP-TEV-Pro(K10R/Y12A)-MTG to obtain fully activated MTG.

Both MTG constructs were expressed in *E. coli* BL21(DE3) in 250 mL of TB medium and the wet weights of cell pellets obtained after expression were measured in triplicate. The average wet weights of cell pellets of MBP-TEV-Pro-MTG and MBP-TEV-Pro(K10R/Y12A)-MTG were 4.2 ± 0.1 g and 1.0 ± 0.1 g, respectively. Introduction of mutations to the propeptide significantly reduced the amount of *E. coli* cells, suggesting that the MTG exhibited its catalytic activity in the cells and resulted in toxic effect. The MTG variants were purified with HisTag affinity chromatography and size-exclusion chromatography (SEC) and the eluates were analyzed with SDS-PAGE (**Fig. 2**). In case of MBP-TEV-Pro-MTG, the bands of the active MTG and cleaved MBP-TEV-Pro were appeared around 38 kDa and 70 kDa, respectively (**Fig. 2A**). The cleaved MBP-TEV-Pro, which lacks HisTag, bound to Ni-NTA column by attaching to the active MTG because of the strong affinity between them. On the other hand, MBP-TEV-Pro(K10R/Y12A)-MTG showed mainly the band of active MTG at around 38 kDa (**Fig. 2B**) and the most of cleaved MBP-TEV-Pro(K10R/Y12A) could be removed from the active MTG. The remaining portion of MBP-TEV-Pro(K10R/Y12A) and highly cross-linked proteins were successfully removed from the active MTG by following SEC purification (**Fig. 2E and 2F**). In contrast, in the SEC purification of MBP-TEV-Pro-MTG, all the active MTG was eluted with the cleaved MBP-TEV-Pro and highly cross-linked proteins (**Fig. 2C and 2D**) and it was impossible to isolate the active MTG. From these results, we concluded that in order to obtain active MTG without any contamination of the propeptide domain, introduction of mutations to the propeptide is essential. Some portions of active MTG were eluted with the cross-linked proteins in SEC purification of MBP-TEV-Pro(K10R/Y12A)-MTG and this is probably due to the avidity effect of the propeptide in the highly cross-linked proteins, which is composed of probably MBP-TEV-Pro(K10R/Y12A) and other endogenous proteins in *E. coli*. We expect that the productivity of MTG can be improved more by reducing the formation of such highly cross-linked proteins by eliminating the cross-linking sites

of MBP-TEV-Pro(K10R/Y12A). Note that the purified active MTG in this study showed no self-cross-linking behavior (**Fig. S1**), which is reported in the previous literature (Rickert et al., 2016).




Fig. 2 Purification of active MTG by using constructs of MBP-TEV-Pro-MTG and MBP-TEV-Pro(K10R/Y12A)-MTG. A and B: SDS-PAGE analyses of fractions in the HisTag purification of MBP-TEV-Pro-MTG and MBP-TEV-Pro(K10R/Y12A)-MTG, respectively. The elution buffer used was 25 mM Tris-HCl, pH7.4, 500 mM NaCl, 500 mM imidazole. C and D: SEC chromatogram and the SDS-PAGE analysis of fractions indicated in the chromatogram of MBP-TEV-Pro-MTG after HisTag purification (A). E and F: SEC chromatogram and the SDS-PAGE analysis of fractions indicated in the chromatogram of MBP-TEV-Pro(K10R/Y12A)-MTG after HisTag purification (B).

After purification, MTG activity measurement was conducted by hydroxamate assay (Folk and Cole, 1966). One unit of MTG activity was defined as the amount of enzyme that catalyzes the formation of 1 μmol of hydroxamate in 1 minute. The specific activities of the active MTGs prepared from MBP-TEV-Pro-MTG and MBP-TEV-Pro (K10R/Y12A)-MTG were 4.0 ± 0.1 U/mg and 22.7 ± 2.6 U/mg, respectively (**Fig. 3**). The active MTG obtained from MBP-TEV-Pro (K10R/Y12A)-MTG showed 5-fold higher specific activity than the one from MBP-TEV-Pro-MTG, because the cleaved propeptide, which has inhibitory effect, remained in the sample prepared from MBP-TEV-Pro-MTG. The specific activity of MTG from MBP-TEV-Pro (K10R/Y12A)-MTG in this study was as high as the activity of previously reported active MTG purified from the original strain (Ando et al., 1989), prepared by in vitro activation of MTG zymogen (Chen et al., 2013) and also that of the commercially available MTG (Zedira, Germany) (25 U/mg). The total amount of active MTG obtained from MBP-TEV-Pro(K10R/Y12A)-MTG was 0.23 mg from 750 mL of TB medium. Since the productivity of MTG in *E. coli* and its activity are in the relationship of trade-off, the amount of active MTG obtained in this study was not high enough for industrial production. However, it is sufficient for use in laboratories and moreover the quality and the specific activity of the obtained MTG were suitable for research uses, which require precise control of reactions.

In conclusion, we demonstrated production of active and soluble MTG by constructing a chimeric protein of TEV protease and MTG zymogen. Introduction of mutations of K10R and Y12A to the propeptide was required to obtain active MTG free of contamination of cleaved propeptide, resulting in successful production of active MTG with a high specific activity.




Fig. 3 Specific activities of the active MTG prepared from two constructs of MTGs measured by hydroxamate assay.

Acknowledgments

This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant number JP19H00841 (to N. K.).

Conflict of interest

The authors declare no financial or commercial conflict of interest.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:

References

- Ando, H., Adachi, M., Umeda, K., Matsuura, A., Nonaka, M., Uchio, R., Tanaka, H., Motoki, M., 1989. Purification and Characteristics of a Novel Transglutaminase Derived from Microorganisms. *Agric. Biol. Chem.* 53, 2613–2617. <https://doi.org/10.1271/bbb1961.53.2613>
- Chen, K., Liu, S., Wang, G., Zhang, D., Du, G., Chen, J., Shi, Z., 2013. Enhancement of *Streptomyces* transglutaminase activity and pro-peptide cleavage efficiency by introducing linker peptide in the C-terminus of the pro-peptide. *J. Ind. Microbiol. Biotechnol.* 40, 317–325. <https://doi.org/10.1007/s10295-012-1221-y>
- Denkler, P., Chiotellis, A., Fischer, E., Brégeon, D., Belmant, C., Gauthier, L., Lhospice, F., Romagne, F., Schibli, R., 2014. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. *Bioconjug. Chem.* 25, 569–578. <https://doi.org/10.1021/bc400574z>
- Folk, J.E., Cole, P.W., 1966. Mechanism of action of guinea pig liver transglutaminase. I. Purification and properties of the enzyme: identification of a functional cysteine essential for activity. *J. Biol. Chem.* 241, 5518–25.
- Griffin, M., Casadio, R., Bergamini, C.M., 2002. Transglutaminases: Nature's biological glues. *Biochem. J.* 368, 377–396. <https://doi.org/10.1042/BJ20021234>
- Hirakawa, H., Kamiya, N., Tanaka, T., Nagamune, T., 2007. Intramolecular electron transfer in a cytochrome P450cam system with a site-specific branched structure. *Protein Eng. Des. Sel.* 20, 453–459. <https://doi.org/10.1093/protein/gzm045>
- Javitt, G., Ben-Barak-Zelas, Z., Jerabek-Willemsen, M., Fishman, A., 2017. Constitutive expression of active microbial transglutaminase in *Escherichia coli* and comparative characterization to a known variant. *BMC Biotechnol.* 17, 1–10. <https://doi.org/10.1186/s12896-017-0339-4>
- Kamiya, N., Abe, H., Goto, M., Tsuji, Y., Jikuya, H., 2009. Fluorescent substrates for covalent protein labeling catalyzed by microbial transglutaminase. *Org. Biomol. Chem.* 7, 3407–3412.

<https://doi.org/10.1039/b904046c>

- Kawai, M., Takehana, S., Takagi, H., 1997. High-level Expression of the Chemically Synthesized Gene for Microbial Transglutaminase from *Streptovorticillium* in *Escherichia coli*. *Biosci. Biotechnol. Biochem.* 61, 830–835. <https://doi.org/10.1271/bbb.61.830>
- Kieliszek, M., Misiewicz, A., 2014. Microbial transglutaminase and its application in the food industry. A review. *Folia Microbiol. (Praha)*. 59, 241–50. <https://doi.org/10.1007/s12223-013-0287-x>
- Kitaoka, M., Mitsumori, M., Hayashi, K., Hiraishi, Y., Yoshinaga, H., Nakano, K., Miyawaki, K., Noji, S., Goto, M., Kamiya, N., 2012. Transglutaminase-mediated in situ hybridization (TransISH) system: A new methodology for simplified mRNA detection. *Anal. Chem.* 84, 5885–5891. <https://doi.org/10.1021/ac2034198>
- Kitaoka, M., Tsuruda, Y., Tanaka, Y., Goto, M., Mitsumori, M., Hayashi, K., Hiraishi, Y., Miyawaki, K., Noji, S., Kamiya, N., 2011. Transglutaminase-mediated synthesis of a DNA-(Enzyme)_n probe for highly sensitive DNA detection. *Chem. - A Eur. J.* 17, 5387–5392. <https://doi.org/10.1002/chem.201003744>
- Marx, C.K., Hertel, T.C., Pietzsch, M., 2008. Purification and activation of a recombinant histidine-tagged pro-transglutaminase after soluble expression in *Escherichia coli* and partial characterization of the active enzyme. *Enzyme Microb. Technol.* 42, 568–575. <https://doi.org/10.1016/j.enzmictec.2008.03.003>
- Marx, C.K., Hertel, T.C., Pietzsch, M., 2007. Soluble expression of a pro-transglutaminase from *Streptomyces mobaraensis* in *Escherichia coli*. *Enzyme Microb. Technol.* 40, 1543–1550. <https://doi.org/10.1016/j.enzmictec.2006.10.036>
- Milczek, E.M., 2018. Commercial Applications for Enzyme-Mediated Protein Conjugation: New Developments in Enzymatic Processes to Deliver Functionalized Proteins on the Commercial Scale. *Chem. Rev.* 118, 119–141. <https://doi.org/10.1021/acs.chemrev.6b00832>
- Motoki, M., Seguro, K., 1998. Transglutaminase and its use for food processing. *Trends Food Sci. Technol.* 9, 204–210. [https://doi.org/10.1016/S0924-2244\(98\)00038-7](https://doi.org/10.1016/S0924-2244(98)00038-7)
- Rickert, M., Strop, P., Lui, V., Melton-Witt, J., Farias, S.E., Foletti, D., Shelton, D., Pons, J., Rajpal, A., 2016. Production of soluble and active microbial transglutaminase in *Escherichia coli* for site-specific antibody drug conjugation. *Protein Sci.* 25, 442–455. <https://doi.org/10.1002/pro.2833>
- Schneider, H., Deweid, L., Avrutina, O., Kolmar, H., 2020. Recent progress in transglutaminase-mediated assembly of antibody-drug conjugates. *Anal. Biochem.* 113615. <https://doi.org/10.1016/j.ab.2020.113615>
- Strop, P., 2014. Versatility of microbial transglutaminase. *Bioconjug. Chem.* 25, 855–862. <https://doi.org/10.1021/bc500099v>
- Takahara, M., Wakabayashi, R., Fujimoto, N., Minamihata, K., Goto, M., Kamiya, N., 2019. Enzymatic Cell-Surface Decoration with Proteins using Amphiphilic Lipid-Fused Peptide Substrates. *Chem. -*

- A Eur. J. 25, 7315–7321. <https://doi.org/10.1002/chem.201900370>
- Takahara, M., Wakabayashi, R., Minamihata, K., Goto, M., Kamiya, N., 2017. Primary Amine-Clustered DNA Aptamer for DNA-Protein Conjugation Catalyzed by Microbial Transglutaminase. *Bioconjug. Chem.* 28, 2954–2961. <https://doi.org/10.1021/acs.bioconjchem.7b00594>
- Tanaka, T., Kamiya, N., Nagamune, T., 2005. N-terminal glycine-specific protein conjugation catalyzed by microbial transglutaminase. *FEBS Lett.* 579, 2092–2096. <https://doi.org/10.1016/j.febslet.2005.02.064>
- Wakabayashi, R., Yahiro, K., Hayashi, K., Goto, M., Kamiya, N., 2017. Protein-Grafted Polymers Prepared Through a Site-Specific Conjugation by Microbial Transglutaminase for an Immunosorbent Assay. <https://doi.org/10.1021/acs.biomac.6b01538>
- Walker, J.A., Bohn, J.J., Ledesma, F., Sorkin, M.R., Kabaria, S.R., Thornlow, D.N., Alabi, C.A., 2019. Substrate Design Enables Heterobifunctional, Dual “click” Antibody Modification via Microbial Transglutaminase. *Bioconjug. Chem.* 30, 2452–2457. <https://doi.org/10.1021/acs.bioconjchem.9b00522>
- Yokoyama, K.I., Nakamura, N., Seguro, K., Kubota, K., 2000. Overproduction of microbial transglutaminase in *escherichia coli*, in vitro refolding, and characterization of the refolded form. *Biosci. Biotechnol. Biochem.* 64, 1263–1270. <https://doi.org/10.1271/bbb.64.1263>